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PREVIOUS clinical studies of Mithramycin have been conducted in the United
States of America. Human pharmacological studies were reported by Curreri
and Ansfield (1960) ; clinical assessment to determine the spectrum of activity
by Parker, Wiltsie and Jackson (1960), Kofman and Ream (1963) and Spear
(1963). The earlier papers suggested that this drug had only limited activity
with early onset of dangerous toxic side effects. However, Kofman (1963)
suggested that careful monitoring during treatment would reveal a wider range
of activity with reduction in toxic side effects, and this was borne out in a careful
survey by Kofman, Medrek and Alexander (1964).
With this information in mind, we have conducted a clinical trial of Mithra-
mycin on a small group (26) of patients with advanced malignant disease. Our
dosage regime was based on the most recent reports on the use ofthe drug (Brown
and Kennedy, 1965). The results recorded are those of the first clinical trial of
the drug in the United Kingdom.
illithramycin
United States Cancer Chemotherapy National Service Center No. 24559.
Synonyms: PA-144. A-2371 (John L. Smith Memorial Foundation).
The spacial molecular structure of this drug is so far unknown, but it has been
credited with a molecular formula (empirical) of C44H70022, with a molecular
weight of 950 + 50. It is a yellow crystalline compound, weakly acid, and is
soluble in water (15 mg. per ml.), ethyl alcohol and acetone. However, it is
stable in solution only at low temperatures and in darkness.
The compound is derived from an actinomycete of the Streptomyces genus.
It is remarkable amongst cytotoxic agents for the absence of nitrogen from its
structure. The drug is supplied in vials containing 2*5 mg. of the pure crystalline
material, and to reduce decomposition to the minimum, these vials must be kept
in cold storage and darkness at -10° C. until immediately before use.
Selection of patients
The first trial of Mithramycin in the United Kingdom has been devoted to a
wide range of cases of advanced nmalignancy, the majority of which had had
previous therapy. The range of tumour types studied is shown in Table I, the
age range in Table II and in the histogram in Fig. 1, and the extent of previous
therapy amongst the patients in the series in Table III.
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TABLE I.-Sites of Primary Lesions and their Cell Types of Patients with
Advanced Malignant Disease Treated with Mithramycin
Site of primary lesion
Breast
Testis
Stomach
Ovary
Pancreas
Caecum
Colon
Rectum
Parotid gland
Thyroid gland
Ileum
Femur
Choroid
Unknown (? ovary)
Total number of
different primary
sites = 13 definite
1 unknown
Histological diagnosis
(Cell type)
Adenocarcinoma
Anaplastic invasive carcinoma
Malignant melanoma
Not determined
Seminoma
Adenocarcinoma
Anaplastic invasive carcinoma
Poorly differentiated
adenocarcinoma
Adenocarcinoma
Adenocarcinoma
Mucus gland carcinoma
Adenocarcinoma
Salivary adenocarcinoma
Anaplastic carcinoma
Leiomyosarcoma
Sarcoma-alveolar celled
Malignant melanoma
Poorly differentiated
adenocarcinoma
No. of Distinct cell types 8
TABLE II.-Age Range of Patients Treated with Mithramycin
Age group
30-39
40-49
50-59
Individual ages
35-35-37-38-38-39
41-45-48-48
51-53-54-56-56-57
60-69 . 63-63-64-65-67
70-79 . 72-74-77-78
80-89 . 81
Numbers
6
4
6
5
4
1
26
Average age = 56 years, approximately.
TABLE III.-Extent of Previous Therapy Given to Patients Presentingfor
Treatment with Mithramycin
Type of treatment
Surgery + radiotherapy + cytotoxic agents
Surgery + radiotherapy .
Surgery + cytotoxic agents
Radiotherapy + cytotoxic agents
Surgery alone
Radiotherapy alone
Cytotoxic agents alone
No previous treatment
Numbers
6
4
2
2
9
1
1
1
Different types and combinations of treatment = 7
Number of patients = 26
Number of
cases
1 (7)
1
* 1
4
2 (3)
1
3
2
2
I
I 1
1
I 1 1
Total number
ofpatients
= 26
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Thirteen confirmed and separate primary sites and an unknown primary site
were selected, from all of which a definitely invasive malignant spread had
occurred. The histopathological features in these cases were varied enough to
ensure a broad survey for therapeutic activity of the drug.
The youngest patient in the series was 35 years of age and the oldest was 81
years, but inspection of Table II and the histogram in Fig. 1 reveals that the
majority (16) were under 60 years, and there is also a large proportion under the
age of 50 years (10 cases).
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FiG. 1. Age range and distributioni of patients undergoing treatment with AMithramycin; the
majority are under 60 years of age, and there is a high proportion under 50.
J)osage
The drug was given at the rate of 25 micrograms per kilogram of body weight
per 24 hours in every case. Bearing in mind the warnings of Kofman and others
regarding the narrow margin between chemotherapeutic effect and toxicity, no
attempt was made to increase the daily dose to an individual maximum toleration.
At the dose-level used, side effects were few, and in most cases easily controlled.
Therapeutic regime
Immediately before administration, the vial containing the drug was taken
from cold storage at -IO' C. and allowed to thaw gently. 10 ml. of sterile
19i58
I I I I I I ITRIAL OF MITHRAMYCIN
glucose-saline ofpH 3.6-3.9 was used to mix and dissolve the drug. The resulting
solution contained 0*25 mg. per ml. The calculated 24 hour alliquot for the
patient was withdrawn and mixed with 500 ml. of sterile glucose-saline solution
at the same pH as for the original mixing and dissolving procedure. The resultant
dilute solution of Mithramycin was then given intravenously: patients in West-
minster Hospital and the Gordon Hospital were given the drug over a period of
12 hours, but those in Queen Alexandria's Military Hospital and in Queen Elizabeth
II Hospital, Welwyn Garden City, were given the drng over 24 hours. With 2
exceptions, all the 26 patients reported here had 8 or 10 alliquots on a 24 hour
basis, but the overall period of time for which the drug was administered varied
from 8 to 14 days because administration of the drug was always stopped at the
onset of troublesome side effects.
Side effects
Side effects were few and consisted most frequently of nausea, occasional
vomiting and headache. Nausea and vomiting were controlled by phenothiazone
compounds in the majority of cases, but in more resistant cases, intramuscular
Droperidol was found effective, although the doses required caused drowsiness.
RESULTS
An analysis of the clinical material used to assess Mithramycin in this trial,
together with a broad classification ofthe results oftreatment, is given in Table IV.
Of the 26 patients who were treated with Mithramycin, the majority (16 cases)
showed no improvement either immediately or during the follow-up period of the
survivors. In this group, the tumours remained unaltered in size or increased,
fresh metastases were discovered, there was failure to gain weight or there was no
improvement in the performance status (Karnofsky et al., 1951). Six patients
benefited by a temporary arrest of their disease, but there was recurrence of the
disease in all cases in under 1 month following cessation of therapy. However,
at the time of writing (January, 1966), 4 of the 26 patients undergoing trial have
slhown a definite quantitative remission.
Within 1 month of commencing treatment, 7 patients had died oftheir disease,
1 patient died during the course of treatment but from causes other than could
be ascribed to drug toxicity, and 1 patient died of congestive cardiac failure
although in at least temporary remission following treatment with Mithramycin.
Of the patients considered to have a temporary remission of their disease,
all were given a specified maximum total dose of 2.0 mg. per kilogram body weight.
All had extensive metastases and had not responded to previous surgery, radio-
therapy or cytotoxic agents. These cases included primary malignant changes
in the colon, pancreas, testis, ovary and included adenocarcinoma, anaplastic
carcinoma, seminoma and leiomyosarcoma cell types.
Definite quantitative remission occurred in 4 of the 26 patients in the trial.
One had an anaplastic invasive carcinoma of the breast, the second an adeno-
carcinoma of the rectum, the third a poorly differentiated cystadenocarcinoma
of the ovary and the last had extensive metastases from a malignant melanoma
originating in the choroid. However, it must be specifically emphasised that our
period of follow-up of these patients is necessarily short and it is, of course,
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TABLE IV.-Summary of Primary Sites of Tumours, Histological Confirmation of Cell
of Administration of Mithramycin, Side Effects and
Site of primary tumour Histopathology (Cell Type)
Group I: No influence on the progress of the disease
1 Left breast Malignant melanoma
2 Left breast Not determined
Spread
Surrounding tissues, skin, bone
Lymph nodes, lung, liver, bone
Left breast
Both breasts
Left breast
Left breast
Stomach
Stomach
Stomach
Carcum
Pancreas
Right parotid gland
Thyroid gland
Right testis
Left Femur
Not determined
Not determined
Adenocarcinoma
Not determined
Anaplastic invasive carcinoma
Anaplastic invasive carcinoma
Anaplastic invasive carcinoma
Mucus-secreting adenocarcinoma
Adenocarcinoma
Salivary mucous gland carcinoma
Anaplastic carcinoma
Seminoma
Alveolar cell sarcoma
16 Not determined Poorly differentiated adenoc
(possibly ovary)
Group II: T'emporary arrest of the disease
17 Colon Mucous gland carcinoma
18 Pancreas Anaplastic adenocarcinoma
19 Left testis Seminoma
20 Left testis Adenocarcinoma
21 Right ovary Poorly differentiated adenoe
carcinoma
carcinoma
Lymph nodes, lung, bone
Skin, lymph nodes, lung, liver
Surrounding tissues, liver, bone
Skin (with fungation), lymph nodes
Lyimjph nodes, liver
Lymph nodes, lung and liver
Soft tissues, lymph nodes, liver, brain
Lymph nodes
Lymph nodes, liver
Lymph nodes, lung
Soft tissues, lymph nodes
Lymph nodes, lung, brain
Soft tissues, lung, bone
Skin, lymph nodes, liver
Skin, lymph nodes, liver
Soft tissues, omentum, liver
Soft tissues, lymph nodes, lung, bone,
brain
Lymph nodes, lung
Lymph nodes, transverse colon, pancreas
22 Ileum Leiomyosarcoma Breast, skin, skeletal muscle, liver,
thyroid, vaginal wall
Group III: Measurable quantitative remission (up to 3 months after treatment)
23 Left breast Anaplastic invasive carcinoma Lymph nodes, bone
24 Rectum Adenocarcinoma Lymph nodes, bone
25 Right ovary
26 Left choroid
Poorly differentiated cystadenocarcinoma Peritoneum (ascites)
Malignant melanoma (amolanotic) Skin (27 countable lesions), lymph nodes,
liver, lung
3
4
5
6
7
8
9
10
11
12
13
14
15
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Type, Extent of Spread, Previous Treatment, Age, Body Weight, Dosage and Time Period
Fate of 26 Patients Participating in the Clinical Trial
Length
of
Previous treatment
Radical mastectomy:
radiotherapy
Bilateral radical mastectomy:
adrenalectomy: oophorec-
tomy: radiotherapy
Adrenalectomy: radiotherapy:
Durabolin: Thiotepa
Prednisone
Radical mastectomy: radio-
therapy: steroids
Radiotherapy: Velbee
Gastro-enterostomy
Total gastrectomy
Gastro-enterostomy
Caecal resection
Laparotomy (inoperable)
Parotidectomy & bloc, dis-
section: radiotherapy
Radiotherapy
Orchidectomy: radiotherapy:
Velbee
Radiotherapy: Velbee:
Leukeran
Laparotomy: radiotherapy:
Thiotepa
Hemicolectomy
Partial pancreatectomy
Orchidectomy: radiotherapy:
Melphalan
Orchidectomy: radiotherapy:
prednisone
Oophorectomy: local resection
of transverse colon
Radical mastectomy: ileal
resections: local excisions:
radiotherapy: Leukeran
Radical mastectomy: oophor-
ectomy: testosterone
Abdomino-perineal excision of
rectum
Oophorectomy
Enucleation of globe: local
excisions: Endoxana
Age
51
56
64
65
72
48
63
63
78
81
45
38
74
38
35
57
53
67
37
35
41
Body Total
weight dose
(kg.) (mg.)
58 12-5
66 13-2
52
57
64
53
65
54
50
50
65
46
46
64
40
46
55
54
45
63
58
treat-
ment
(days)
10
1
10-4
11-3
1 6
10-0
12-8
10-4
10-0
10-0
12-8
9-2
5-8
16-0
8-0
12-8
12-4
10-4
11 2
12-6
14-4
Side effects Fate
Intermittent hyperpyrexia Many new lesions
L4 Nausea, vomiting-
disrupting treatment
10 -None
8 Nausea
1 Nausea, vomiting,
headache
8 Nausea
8
8
8
8
8
8
5
10
10
8
9
8
10
9
10
Nausea: abdominal
distension
Nausea
Anorexia: epileptic fits
Anorexia: oedema:
nausea
Nausea, vomiting:
headache
Headache: leucopenia
Laryngeal obstruction
Nausea
Nausea, vomiting
Nausea, vomiting
Thrombocytopenia
Nausea
Anorexia: nausea
None
Nausea
48 60 15-0 10 -None
39
77
60
64
9-6 8
12-8 8
Nausea: headache
Anorexia: nausea
56 47 9-4 8 Nausea: headache
54 53 10-4 8 -None
General deterioration
General deterioration
General deterioration
Patient refused further
treatment
Gained weight during
course rapid loss after
cessation
Slow deterioration
Rapid deterioration
Died 3 days after treat-
ment ceased
Progressive deterioration
Died during treatment
Died 6 weeks after treat-
ment ceased
Died 5 weeks after treat-
ment ceased
Died 3 months after
treatment ceased
Temporary remission of
skin lesions
Died 6 weeks after treat-
ment ceased
Gained weight after
treatment ceased
Regression of mass in
neck, but general de-
terioration began within
1 month
New nodules within 5
weeks of end of treat-
ment
Complete remission of
pain and paraplegia
Remission of paraplegia:
died of congestive
cardiac failure 4 weeks
after treatment ceased
Disappearance of ascites
Excellent symptomatic
improvement: disap-
pearance of 7 skin
lesions
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impossible to forecast for how long the remission in this last group of patients will
be maintained.
Comments have already been made on side effects in connection with the
plan and execution of therapy for this trial. Seventeen patients suffered from
nausea, 12 ofwhom required therapeutic control, but only 5 progressed to trouble-
some vomiting necessitating more rigorous treatment than administration of
phenothiazone compounds. An unexpected accompaniment of Mithramycin
administration was dizziness and headache, which responded poorly to analgesics
and antihistamines: one patient had several epileptic fits but was found at
autopsy to have multiple cerebral metastases. In only 2 patients were side effects
severe enough to demand temporary cessation of the trial. and only 1 patient did
not complete the course of Mithramycin therapy from choice. Anorexia occurred
in 4 patients, all of whom were cachectic before treatment was commenced.
Apart from 1 instance of leucopenia and one of relative thrombocytopenia, there
were no serious adverse effects on erythropoeiesis, leucopoeiesis or the coagulating
factors, nor were adverse effects on liver function discovered.
DISCUSSION
The present position of cytotoxic agents in the treatment of malignant disease
is controversial. Both clinicians and laboratory workers are more aware of the
complexity of the problem and would appear to accept the fact that these agents
are still in the experimental stage as regards the control of neoplastic changes in
man. Particular aspects of this problem are fully discussed by Davis (1965).
The closest co-operation between the laboratory and the ward cannot be too fully
stressed, and this is particularly important when new agents which show promise
from laboratory testing are investigated for their clinical effects. Carefully
controlled animal experiments must be followed by equally carefully controlled
clinical trials. In this respect, the phasing of clinical trials as discussed in the
World Health Organization Technical Report No. 232 (1962) is logical in its
concept and is reasonably practicable in its application.
The clinical pharmacology of Mithramycin was reported by Curreri and
Ansfield (1960), but these authors did not discuss in detail some haematological
factors of importance, although they did stress that thrombocytopenia occurred
when not expected from the results of animal experiments. Later, clinical
assessment for spectrum of activity by Parker, Wiltsie and Jackson (1960) sug-
gested that the range of usefulness of Mithramycin was overshadowed by its
toxicity. Such toxicity was most likely due to their method of administration
in single calculated daily intravenous doses. Kofman (1963) points out that a
reduction in dose rate and the use of continuous intravenous infusion mitigates
toxicity, reduces side effects and broadens the spectrum of activity. Even so,
careful assessment of the reports by Kofman and Ream (1963), Spear (1963), and
Kofman, Medrek and Alexander (1964) shows that very few cell types and even
fewer sites of primary growth are susceptible to cytotoxic activity when treated
with Mithramycin. In fact, the only cases in which unequivocal remission has
occurred are those ofmalignant disease ofthe testis and ovary, which is supported
by the trials conducted by Brown and Kennedy (1965).
As outlined above, we have conducted a first trial in the United Kingdom of
Mithramycin for its effect on advanced malignant disease. Our results from this
trial show that the spectrum ofactivity ofthis drug is limited amongst the different
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cell types studied and the primary sites represented in this series. Quantitative
or even temporary remission was confined to a small proportion of the cases
selected for study (up to the time ofwriting). These included cases ofmalignant
changes in both the testis and the ovary and would certainly support the findings
of Kofman, Medrek and Alexander (1964) and those of Brown and Kennedy
(1965); our impression, therefore, is that Mithramycin may have some specific
and beneficial effect on neoplastic changes arising in reproductive tissue. How-
ever, we are fully aware that all our patients were in an advanced stage of their
disease; the fact that there had been little or no response to previous therapy was
a fair indication that dramatic response to yet another cytotoxic agent was only
a remote possibility.
The absence of overwhelming toxicity from the drug may indicate insufficient
dosage, but thereports ofothers suggest that our daily dose was as high as possible,
compatible with the very narrow effective therapeutic range of the drug. It has
been suggested that final therapeutic effect may be delayed for many weeks and
that remission can only be maintained by further courses of the drug. There is,
therefore, the possibility that in some of the cases where temporary remission
occurred, further courses of the drug may have had a more quantitative and
lasting effect. Our preliminary investigations would indicate that further trials
using more prolonged and repeated courses in patients showing response should
be performed.
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